Condition: Autism Spectrum Disorder · Sponsor: Changping Laboratory
The aim of this trial is to assess the efficacy and safety of precision neuromodulation for alleviating core symptoms in patients with autism spectrum disorder (ASD) who also have intellectual or developmental delay. The neuromodulation will be administered using intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC), guided by personalized Brain Functional Sector (pBFS) technology.
This description comes directly from the study's public registry record.
Qi Liu, Ph.D. · 010-80726688 · liuqi@cpl.ac.cn
Always discuss trial participation with your own doctor first.
| Fujian Children's Hospital | Fuzhou, Fujian, China | Recruiting |
| Fujian Maternity and Child Health Hospital | Fuzhou, Fujian, China | Recruiting |
| Hebei Provincial Mental Health Center | Baoding, Hebei, China | Recruiting |
| Xi'an TCM Hospital of Encephalopathy | Xi'an, Shaanxi, China | Recruiting |
| Jining Medical University | Jining, Shandong, China | Recruiting |
| Linyi Hedong Rehabilitation Hospital | Linyi, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06255535